BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jakubowska MA, Kerkhofs M, Martines C, Efremov DG, Gerasimenko JV, Gerasimenko OV, Petersen OH, Bultynck G, Vervliet T, Ferdek PE. ABT-199 (Venetoclax), a BH3-mimetic Bcl-2 inhibitor, does not cause Ca2+ -signalling dysregulation or toxicity in pancreatic acinar cells. Br J Pharmacol 2019;176:4402-15. [PMID: 30266036 DOI: 10.1111/bph.14505] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Wang X, Galli G, Campanella M. Mitochondrial pharmacology: featured mechanisms and approaches for therapy translation. Br J Pharmacol 2019;176:4245-6. [PMID: 31793696 DOI: 10.1111/bph.14820] [Reference Citation Analysis]
2 de Ridder I, Kerkhofs M, Veettil SP, Dehaen W, Bultynck G. Cancer cell death strategies by targeting Bcl-2's BH4 domain. Biochim Biophys Acta Mol Cell Res 2021;1868:118983. [PMID: 33549704 DOI: 10.1016/j.bbamcr.2021.118983] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
3 Distelhorst CW, Bootman MD. Creating a New Cancer Therapeutic Agent by Targeting the Interaction between Bcl-2 and IP3 Receptors. Cold Spring Harb Perspect Biol 2019;11:a035196. [PMID: 31110129 DOI: 10.1101/cshperspect.a035196] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
4 Jakubowska MA, Kerkhofs M, Martines C, Efremov DG, Gerasimenko JV, Gerasimenko OV, Petersen OH, Bultynck G, Vervliet T, Ferdek PE. ABT-199 (Venetoclax), a BH3-mimetic Bcl-2 inhibitor, does not cause Ca2+ -signalling dysregulation or toxicity in pancreatic acinar cells. Br J Pharmacol 2019;176:4402-15. [PMID: 30266036 DOI: 10.1111/bph.14505] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
5 Bustos G, Ahumada-Castro U, Silva-Pavez E, Puebla A, Lovy A, Cesar Cardenas J. The ER-mitochondria Ca2+ signaling in cancer progression: Fueling the monster. Int Rev Cell Mol Biol 2021;363:49-121. [PMID: 34392932 DOI: 10.1016/bs.ircmb.2021.03.006] [Reference Citation Analysis]
6 Rosa N, Ivanova H, Wagner LE 2nd, Kale J, La Rovere R, Welkenhuyzen K, Louros N, Karamanou S, Shabardina V, Lemmens I, Vandermarliere E, Hamada K, Ando H, Rousseau F, Schymkowitz J, Tavernier J, Mikoshiba K, Economou A, Andrews DW, Parys JB, Yule DI, Bultynck G. Bcl-xL acts as an inhibitor of IP3R channels, thereby antagonizing Ca2+-driven apoptosis. Cell Death Differ 2021. [PMID: 34750538 DOI: 10.1038/s41418-021-00894-w] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Mabonga L, Kappo AP. Protein-protein interaction modulators: advances, successes and remaining challenges. Biophys Rev 2019;11:559-81. [PMID: 31301019 DOI: 10.1007/s12551-019-00570-x] [Cited by in Crossref: 55] [Cited by in F6Publishing: 50] [Article Influence: 18.3] [Reference Citation Analysis]
8 Ivanova H, Vervliet T, Monaco G, Terry LE, Rosa N, Baker MR, Parys JB, Serysheva II, Yule DI, Bultynck G. Bcl-2-Protein Family as Modulators of IP3 Receptors and Other Organellar Ca2+ Channels. Cold Spring Harb Perspect Biol 2020;12:a035089. [PMID: 31501195 DOI: 10.1101/cshperspect.a035089] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 10.0] [Reference Citation Analysis]